SCHEMBL17469559

SCHEMBL17469559

CN(C)C/C=C/C(=O)Nc1ccc2c(c1)C(=O)N(C)c1cnc(N)nc1N2C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 6/20 0.45
▸ AURKB Q96GD4 6/20 0.45
▸ BRD4 O60885 3/20 0.45
▸ PLK4 O00444 2/20 0.45
▸ LRRK2 Q5S007 2/20 0.45
▸ AURKC Q9UQB9 2/20 0.45
▸ PIK3CD O00329 5/20 0.43
▸ PIK3C2G O75747 5/20 0.43
▸ PIK3CG P48736 5/20 0.43
▸ PIK3CA P42336 1/20 0.41
▸ EGFR P00533 6/20 0.41
▸ ERBB2 P04626 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ ITK Q08881 5/20 0.40
▸ BTK Q06187 4/20 0.40
▸ JAK3 P52333 2/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ BLK P51451 1/20 0.40
▸ PLCG1 P19174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469565 0.85 EGFR (0.43) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL17469564 0.85 MAPK7 (0.50) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL16065777 0.79 DCLK1 (0.59) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL16065773 0.79 ITK (0.59) AURKAAURKBLRRK2PIK3CDPIK3C2G
SCHEMBL20682528 0.78 DCLK1 (0.43) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL17469527 0.73 CCNK (0.46) —
SCHEMBL20875242 0.71 PIK3CD (0.59) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL18948298 0.69 CDK7 (0.35) AURKAAURKBBRD4PLK4LRRK2
SCHEMBL10098766 0.68 DCLK1 (0.58) AURKAAURKBBRD4LRRK2PIK3CD
SCHEMBL25735908 0.67 BRD4 (0.43) BRD4EGFRERBB2KDRITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787461-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-29 — — US disclosed
US-20200071340-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-03-05 — — US disclosed
US-10457692-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-29 — — US disclosed
US-20190084998-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-03-21 — — US disclosed
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-01-29 — — US disclosed
US-20170283422-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2017-10-05 — — US disclosed
US-9676792-B2 Pyrimido-diazepinone compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-06-13 — — US disclosed
US-20160024115-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071340-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-20190084998-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-10787461-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-10189861-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-20170283422-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-10457692-B2 Pyrimido-diazepinone compounds and methods of treating disorders BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885
US-20160024115-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, GRK3, BRSK1 AURKA 99/4885AURKB 118/4885BRD4 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback